Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	33.7	35.56	28.6	24.63	15.69	15.89
Cash & Short-Term Investments	33.7	35.56	28.6	24.63	15.69	15.89
Cash Growth	14.65%	24.34%	16.12%	57.00%	-1.29%	9.78%
Accounts Receivable	14.55	13.19	11.71	10.7	8.65	6.83
Other Receivables	-	0.45	0.29	0.51	0.33	0.28
Receivables	14.55	13.64	12	11.22	8.98	7.12
Inventory	14.53	15.08	16.6	11.15	15.41	11.31
Prepaid Expenses	-	0.68	0.77	0.59	0.61	0.48
Other Current Assets	1.96	0.88	0.93	0.7	0.47	0.31
Total Current Assets	64.75	65.85	58.9	48.29	41.16	35.1
Property, Plant & Equipment	11.99	12.48	10.33	9.17	8.47	8.26
Other Intangible Assets	0.02	0.04	0.05	0.03	0.01	-
Long-Term Deferred Tax Assets	3.7	4	2.62	2.32	2.16	1.9
Total Assets	80.47	82.36	71.89	59.81	51.8	45.27

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	12.77	6.73	5.58	5.58	4.5	3.82
Accrued Expenses	2.62	3.55	2.83	2.31	2.02	2.15
Current Portion of Leases	0.49	0.48	0.3	0.21	0.3	0.19
Current Income Taxes Payable	1.2	1.62	0.58	0.07	0.04	0.97
Other Current Liabilities	5.86	11.79	9.99	8.05	8.01	7.34
Total Current Liabilities	22.94	24.17	19.27	16.22	14.86	14.46
Long-Term Leases	1.67	1.91	0.21	0.18	0.3	0.18
Pension & Post-Retirement Benefits	0.15	0.13	0.12	0.08	0.14	0.13
Long-Term Deferred Tax Liabilities	-	-	-	-	-	0.07
Total Liabilities	24.76	26.2	19.61	16.48	15.3	14.85

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	41.98	42.79	45.03	42.57	41.9	41.63
Retained Earnings	5.59	5.2	0.85	-2.77	-8.48	-12.53
Comprehensive Income & Other	8.25	8.26	6.48	3.6	3.15	1.65
Total Common Equity	55.81	56.25	52.35	43.4	36.57	30.75
Minority Interest	-0.11	-0.09	-0.07	-0.07	-0.07	-0.33
Shareholders' Equity	55.71	56.16	52.28	43.33	36.5	30.42
Total Liabilities & Equity	80.47	82.36	71.89	59.81	51.8	45.27

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2.16	2.39	0.52	0.39	0.6	0.37
Net Cash (Debt)	31.55	33.17	28.08	24.24	15.09	15.52
Net Cash Growth	16.19%	18.11%	15.84%	60.69%	-2.79%	25.11%
Net Cash Per Share	0.56	0.58	0.50	0.44	0.28	0.29
Filing Date Shares Outstanding	54.39	55.5	56.56	56.4	56.53	55.19
Total Common Shares Outstanding	54.39	55.5	56.56	56.4	56.53	55.19
Working Capital	41.81	41.68	39.62	32.07	26.3	20.64
Book Value Per Share	1.03	1.01	0.93	0.77	0.65	0.56
Tangible Book Value	55.79	56.22	52.3	43.37	36.56	30.75
Tangible Book Value Per Share	1.03	1.01	0.92	0.77	0.65	0.56
Land	-	9.84	9.62	8.51	7.93	7.83
Machinery	-	2.83	2.26	1.88	1.83	1.99
Construction In Progress	-	-	-	0.48	-	-
Leasehold Improvements	-	0.3	0.3	0.12	0.13	0.14

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 18, 2026

Data Sources Report a data error